Information on EC 2.7.4.21 - inositol-hexakisphosphate kinase

Word Map on EC 2.7.4.21
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
2.7.4.21
-
RECOMMENDED NAME
GeneOntology No.
inositol-hexakisphosphate kinase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
ATP + 1D-myo-inositol 1-diphosphate 2,3,4,5,6-pentakisphosphate = ADP + 1D-myo-inositol 1,5-bis(diphosphate) 2,3,4,6-tetrakisphosphate
show the reaction diagram
(2)
-
-
-
ATP + 1D-myo-inositol hexakisphosphate = ADP + 1D-myo-inositol 5-diphosphate 1,2,3,4,6-pentakisphosphate
show the reaction diagram
(1)
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
phospho group transfer
phospho-group transfer
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
inositol pyrophosphates biosynthesis
-
-
SYSTEMATIC NAME
IUBMB Comments
ATP:1D-myo-inositol-hexakisphosphate 5-phosphotransferase
Three mammalian isoforms are known to exist.
CAS REGISTRY NUMBER
COMMENTARY hide
176898-37-6
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
gene IP6K1
SwissProt
Manually annotated by BRENDA team
gene KCS1
UniProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
evolution
malfunction
metabolism
physiological function
additional information
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
ATP + 1D-myo-inositol 1-diphosphate 2,3,4,5,6-pentakisphosphate
ADP + 1D-myo-inositol 1,3-bis(diphosphate) 2,4,5,6-tetrakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol 1-diphosphate 2,3,4,5,6-pentakisphosphate
ADP + 1D-myo-inositol 1-triphosphate 2,3,4,5,6-pentakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol 1-diphosphate pentakisphosphate
ADP + 1D-myo-inositol 1,5-bis(diphosphate) 2,3,4,6-tetrakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol 5-diphosphate 1,2,3,4,6-pentakisphosphate
ADP + 1D-myo-inositol 1,5-bis(diphosphate) 2,3,4,6-tetrakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol 5-diphosphate 2,3,4,5,6-pentakisphosphate
ADP + 1D-myo-inositol 1,5-bis(diphosphate) 2,3,4,6-tetrakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol hexakisphosphate
ADP + 1-diphospho-1D-myo-inositol 2,3,4,5,6-pentakisphosphate
show the reaction diagram
-
-
-
r
ATP + 1D-myo-inositol hexakisphosphate
ADP + 1D-myo-inositol 1-diphosphate 2,3,4,5,6-pentakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol hexakisphosphate
ADP + 1D-myo-inositol 3-diphosphate 1,2,4,5,6-pentakisphosphate
show the reaction diagram
-
-
-
-
?
ATP + 1D-myo-inositol hexakisphosphate
ADP + 1D-myo-inositol 5-diphosphate 1,2,3,4,6-pentakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol hexakisphosphate
ADP + 5-diphospho-1D-myo-inositol (1,2,3,4,6)-pentakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol hexakisphosphate
ADP + 5-diphospho-1D-myo-inositol 1,2,3,4,6-pentakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol hexakisphosphate
ADP + diphosphoinositol pentakisphosphate + bisdiphosphoinositol tetrakisphosphate
show the reaction diagram
-
-
-
-
?
ATP + 1D-myo-inositol-1,3,4,5,6-pentakisphosphate
ADP + diphospho-1D-myo-inositol tetrakisphosphate
show the reaction diagram
-
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
ATP + 1D-myo-inositol 1-diphosphate pentakisphosphate
ADP + 1D-myo-inositol 1,5-bis(diphosphate) 2,3,4,6-tetrakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol 5-diphosphate 1,2,3,4,6-pentakisphosphate
ADP + 1D-myo-inositol 1,5-bis(diphosphate) 2,3,4,6-tetrakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol 5-diphosphate 2,3,4,5,6-pentakisphosphate
ADP + 1D-myo-inositol 1,5-bis(diphosphate) 2,3,4,6-tetrakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol hexakisphosphate
ADP + 1D-myo-inositol 1-diphosphate 2,3,4,5,6-pentakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol hexakisphosphate
ADP + 1D-myo-inositol 5-diphosphate 1,2,3,4,6-pentakisphosphate
show the reaction diagram
ATP + 1D-myo-inositol hexakisphosphate
ADP + 5-diphospho-1D-myo-inositol 1,2,3,4,6-pentakisphosphate
show the reaction diagram
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1,3,4,5,6-inositol pentakisphosphate
-
IC50 for inositol hexakisphosphate kinase activity is 0.022 mM, IC50 for ATP synthase activity is 0.0128 mM
2,5-O-benzyl-myo-inositol 1,3,4,6-tetrakisphosphate
activates the ATP hydrolysis activity and inhibits the PPIP5K2 activity and InsP6 kinase activity, and the 1,5-[PP]2-InsP4 dephosphorylation activity of the enzyme. The compound can inhibit inositol phosphate kinase activity without occupying the catalytic site
-
2-O-benzyl-5-O-alpha-phosphonoacetyl-myo-inositol 1,3,4,6-tetrakisphosphate
stimulates ATP hydrolysis 9fold, but inhibits 1,5-[PP]2-InsP4 dephosphorylation activity of the enzyme. The compound can inhibit inositol phosphate kinase activity without occupying the catalytic site
-
2-O-benzyl-5-O-diphosphate-myo-inositol 1,3,4,6-tetrakisphosphate
activates ATP hydrolysis activity but inhibits 1,5-[PP]2-InsP4 dephosphorylation activity of the enzyme
-
2-O-benzyl-myo-inositol 1,2,3,4,6-pentakisphosphate
activates ATP hydrolysis activity but inhibits 1,5-[PP]2-InsP4 dephosphorylation activity of the enzyme
-
5-O-alpha-diphosphate-myo-inositol 1,3,4,6-tetrakisphosphate
activates ATP hydrolysis activity but inhibits 1,5-[PP]2-InsP4 dephosphorylation activity of the enzyme
-
5-O-alpha-phosphonoacetyl-myo-inositol 1,2,3,4,6-pentakisphosphate
stimulates ATP hydrolysis 5fold, but inhibits 1,5-[PP]2-InsP4 dephosphorylation activity of the enzyme
-
diphosphoinositol pentakisphosphate
-
IC50 for inositol hexakisphosphate kinase activity is 0.0066 mM, IC50 for ATP synthase activity is 0.0018 mM
EDTA
-
-
H2O2
-
H2O2 as low as 0.1 mM dramatically reduces enzymatic activity
heat shock protein Hsp90
-
binding of HSP90 inhibits IP6K2 catalytic activity, IP6K2 binds to HSP90's C terminus. Depletion of HSP90 by RNAi in HEK-293 cells increases IP6K catalytic activity about 2.5fold, specificity of IP6K2-HSP90 interaction, overview. Drugs and selective mutations that abolish HSP90IP6K2 binding elicit activation of IP6K2, leading to cell death. Overexpression of HSP90 markedly and specifically reduces IP6K catalytic activity in HEK-293 cells, overexpression of HSP90 does not influence catalytic activity of IP6K1
-
inositol 1,2,4,5,6-pentakisphosphate
-
IC50 for inositol hexakisphosphate kinase activity is 0.022 mM
Inositol 1,3,4,5-tetrakisphosphate
-
IC50 for inositol hexakisphosphate kinase activity is 0.061 mM, IC50 for ATP synthase activity is 0.0325 mM
Inositol 1,4,5-trisphosphate
-
IC50 for ATP synthase activity is 0.253 mM
Inositol hexakisphosphate
-
IC50 for inositol hexakisphosphate kinase activity is 0.0008 mM, IC50 for ATP synthase activity is 0.0018 mM
N(2)-(m-(trifluoromethyl)benzyl) N(6)-(p-nitrobenzyl)purine
N2-(3-(trifluoromethyl)benzyl)-N6-(4-nitrobenzyl)purine
-
-
N2-(3-trifluorobenzyl)-N6-(4-nitrobenzyl)purine
-
N2-(m-(trifluoromethy)lbenzyl)N6-(p-nitrobenzyl)purine
-
potent and selective inhibitor
-
N2-(m-(trifluoromethyl) benzyl) N6-(p-nitrobenzyl) purine
TNP, a selective inhibitor, abolishes the basal and Cx43-potentiated Runx2 activity in response to FGF2 treatment relative to DMSO treated controls
-
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
2,5-O-benzyl-myo-inositol 1,3,4,6-tetrakisphosphate
activates the ATP hydrolysis activity and inhibits the InsP6 kinase activity of the enzyme
-
2-O-aminoethyl-myo-inositol 1,2,3,4,6-pentakisphosphate
-
-
2-O-benzoyl-myo-inositol 1,2,3,4,6-pentakisphosphate
-
-
2-O-benzyl-5-O-alpha-phosphonoacetyl-myo-inositol 1,3,4,6-tetrakisphosphate
stimulates ATP hydrolysis 9fold
-
2-O-benzyl-5-O-diphosphate-myo-inositol 1,3,4,6-tetrakisphosphate
-
-
2-O-benzyl-myo-inositol 1,2,3,4,6-pentakisphosphate
-
-
2-O-butanoyl-myo-inositol 1,2,3,4,6-pentakisphosphate
-
-
5-O-alpha-diphosphate-myo-inositol 1,3,4,6-tetrakisphosphate
-
-
5-O-alpha-phoshonoacetyl-myo-inositol 1,3,4,6-tetrakisphosphate
-
-
5-O-alpha-phosphonoacetyl-myo-inositol 1,2,3,4,6-pentakisphosphate
stimulates ATP hydrolysis 5fold
-
interferon beta
-
treatment with interferon beta enhances binding of IHPK2 to TNF receptor-associated factor 2
-
interferon-beta
-
induces IHPK2 activity after 4 h exposure
-
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00039
1D-myo-inositol hexakisphosphate
isoform PPIP5K2, in 20 mM HEPES-NaOH pH 7.2, 50 m MKCl, at 37C
0.00197
5-diphospho-1D-myo-inositol (1,2,3,4,6)pentakisphosphate
-
pH 6.8, 37C
1.57
ADP
-
pH 6.8, 37C
0.037 - 1.4
ATP
0.0055
D-myo-inositol-1,3,4,5,6-pentakisphosphate
pH 7.0, 37C
0.0007 - 0.0061
Inositol hexakisphosphate
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.03
1D-myo-inositol hexakisphosphate
Homo sapiens
O43314
isoform PPIP5K2, in 20 mM HEPES-NaOH pH 7.2, 50 mM KCl, at 37C
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
76
1D-myo-inositol hexakisphosphate
Homo sapiens
O43314
isoform PPIP5K2, in 20 mM HEPES-NaOH pH 7.2, 50 mM KCl, at 37C
5734
0.79
ATP
Homo sapiens
O43314
isoform PPIP5K2, using 1D-myo-inositol hexakisphosphate as cosubstrate, in 20 mM HEPES-NaOH pH 7.2, 50 mM KCl, at 37C
4
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0128
1,3,4,5,6-inositol pentakisphosphate
Rattus norvegicus
-
IC50 for inositol hexakisphosphate kinase activity is 0.022 mM, IC50 for ATP synthase activity is 0.0128 mM
0.0018
diphosphoinositol pentakisphosphate
Rattus norvegicus
-
IC50 for inositol hexakisphosphate kinase activity is 0.0066 mM, IC50 for ATP synthase activity is 0.0018 mM
0.0325
His3Cd-GST-protein
Rattus norvegicus
-
IC50 for inositol hexakisphosphate kinase activity is 0.061 mM, IC50 for ATP synthase activity is 0.0325 mM
-
0.253
human skin elastin
Rattus norvegicus
-
IC50 for ATP synthase activity is 0.253 mM
-
0.022
inositol 1,2,4,5,6-pentakisphosphate
Rattus norvegicus
-
IC50 for inositol hexakisphosphate kinase activity is 0.022 mM
0.0018
Inositol hexakisphosphate
Rattus norvegicus
-
IC50 for inositol hexakisphosphate kinase activity is 0.0008 mM, IC50 for ATP synthase activity is 0.0018 mM
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7 - 7.5
assay at
7.4
-
assay at
7.5
-
assay at
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
male, isozymes AtIPK2alpha and AtIPK2beta have overlapping expression in male gametophyte; male, isozymes AtIPK2alpha and AtIPK2beta have overlapping expression in male gametophyte
Manually annotated by BRENDA team
MC-3T3 osteoblasts express IP6K1 and IP6K2 mRNA more than 25fold more abundantly than IP6K3; MC3T3 osteoblasts express IP6K1 and IP6K2 mRNA more than 25fold more abundantly than IP6K3; MC3T3 osteoblasts express IP6K1 and IP6K2 mRNA more than 25fold more abundantly than IP6K3
Manually annotated by BRENDA team
-
cell culture
Manually annotated by BRENDA team
isozyme IP6K3 is highly concentrated in the brain in cerebellar Purkinje cells
Manually annotated by BRENDA team
co-localization with phosphorylated TDP-43 of InsP6K2 in the cytoplasm of anterior horn cells of the spinal cord
Manually annotated by BRENDA team
faintly expressed
Manually annotated by BRENDA team
additional information
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
low level of activity
Manually annotated by BRENDA team
additional information
-
IP6K1 exhibits dual localization in the cytoplasm and nucleus
-
Manually annotated by BRENDA team
PDB
SCOP
CATH
ORGANISM
UNIPROT
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
49200
-
calculated from amino acid sequence
54000
-
1 * 54000, SDS-PAGE
57000
-
SDS-PAGE
60000
-
gel filtration
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
monomer
additional information
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
phosphoprotein
-
the phosphorylation of IP6K1 at a PKC/PKA motif modulates its interaction with PLIN1 and lipolysis. GST-IP6K1 phosphorylation in HEK293 cells is enhanced by forskolin-mediated PKA activation. Endogenous IP6K1 phosphorylation in HEK293 cells is enhanced to a greater extent by PKC activation compared to PKA activation as evidenced by PMA and FSK treatments. No phosphorylation of IP6K1 mutant S118A-S121A in HEK293 cells
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
purified recombinant MBP-tagged EhIP6KA residues 32-270, several crystal complexes of the IP6K including those that contain either large (Ins(1,3,4,5,6)P5 /InsP6) or small (Ins(1,4,5)P3) substrates, hanging drop vapor diffusion, 60 mg/ml protein in solution is mixed with reservoir solution containing 12% w/v PEG 3350, 50 mM NaH2PO4, pH 5.5 at 18C, or by hanging drop vapor diffusion for one week against a well buffer containing 8% w/v PEG 3350, 100 mM Na3citrate, pH 5.2 at 25C, followed by dilution microseeding for two weeks with a well buffer of 8% w/v PEG 3350, 100 mM Na3citrate, pH 5.2, and 8% ethylene glycol at 25C, soaking of crystals in 22% w/v PEG 3350, 10 mM MgCl2, 10 mM ATP, 0.1 M sodium acetate, pH 5.2, and 20 mM InsP6, 10 mM Ins(1,3,4,5,6)P5 or 10 mM Ins(1,4,5)P3 for 3 days, X-ray diffraction structure determination and analysis, molecular replacement using MBP (1ez9) and IP3K (1w2c) as search models
N-terminally truncated enzyme mutant, residues 41-366, hanging drop vapor diffusion against a well buffer of 12% w/v PEG 3350, 20 mM MgCl2, 0.1 M HEPES, pH 7.0, 0,1 mM AMP-PNP, and 2 mM CdCl2 at 4C, 3 days, 4C, X-ray diffraction structure determination and analysis
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-70C, 20% glycerol, optimal stability
-
4C, 7 days, 50% loss of activity
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
glutathione Sepharose column chromatography, and gel filtration
-
GSTrap HP column chromatography
recombinant wild-type and truncated mutant enzymes
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
expressed in Escherichia coli BL21 cells
-
expressed in Escherichia coli BL21(DE3) cells
expressed in NIH-OVCAR-3 cells
-
expression in Escherichia coli
expression in Escherichia coli and HEK-293T cells, additionally wild-type IHPK2 and the NLS mutant is cloned into the pCXN2 mammalian expression vector and electroporated into NIH-OVCAR-3 cells
-
expression in Escherichia coli, NIH-OVCAR-3 and Hey ovarian carcinoma cells, IP6K2 mRNA is not induced in NIH-OVCAR-3 cells following treatment with interferon-beta or gamma-irradiation, both gamma-irradiation and interferon-beta induce IP6K2 protein via a post-translational mechanism
-
expression in HeLa cells, PC12 cells, Jurkat T cells, OVCAR-3 cells, HL-60 cells and HEK-293 cells
-
expression of the wild-type enzyme in Saccharomyces cerevisiae mutant strains, overexpression of the GST-tagged or Myc-tagged enzyme in HEK-293, HeLa, and HCT116 cells, expression of wild-type and mutant enzymes in HEK-293 cells
-
gene Ihpk1, located on chromosome 9, has 6 exons, of which exon 1 is exclusively noncoding, the start codon is located in exon 2, and the stop codon is located in exon 6, DNA and amino acid sequence determination and analysis. Expressionin MEF cell lines
-
gene IMPKb; gene IPMKa,
gene IP6K1
gene Ip6k1, expression of murine IP6K1 rescues yeast kcs1DELTA inositol auxotrophy. Nuclear recombinant expression of GFP-tagged wild type IP6K1 in IP6K1 knockout cells
-
gene ip6k1, quantitative real-time PCr enzyme expression analysis; gene ip6k2, quantitative real-time PCr enzyme expression analysis; gene ip6k3, quantitative real-time PCr enzyme expression analysis
gene IP6K1, recombinant coexpression of GST-tagged wild-type and mutant enzymes with Myc-tagged PLIN1 in HEK-293 cells, recombinant expression of Myc-tagged enzyme
-
gene IP6K1, recombinant expression of GST-tagged enzyme in Escherichia coli strain BL21(DE3), coexpression of IP6K1 prevents enhancement of ubiquitylation by the expression of DDB1/Cul4A in HEK293 cells. IP6K1 expression of shRNA-resistant mouse IP6K1 in IP6K1 knockdown cells, overexpression of TAP-IP6K1 in HEK-293 cells
-
gene vip1, phylogenetic analysis, AtVip1 restores InsP7 synthesis in a Saccharomyces cerevisiae kcs1 mutant; gene vip2, phylogenetic analysis, AtVip2 restores InsP7 synthesis in a Saccharomyces cerevisiae kcs1 mutant
-
GST fusion protein is transfected into HEK293T cells
overexpression of wild-type and inactive mutant IHPK2 in ovarian carcinoma cell lines
-
recombinant co-overexpression of InsP6K2 and C-terminal residues 219-414 of TDP-43 from InsP6K2-pDsRed tag and TDP219-pEGFP tag plasmids in SHSY-5Y cells. Transfection of SHSY-5Y cells with a plasmid encoding a catalytically inactive, dominant-negative InsP6K2 (K2 K/A). HSP90 protein expression is reduced in the cytoplasmic fraction of TDP219- and InsP6K2-transfected cells. HSP90 expression is also significantly reduced in cells doubly transfected with TDP219M and InsP6K2 compared with control cells
recombinant expression of MBP-tagged EhIP6KA residues 32-270
recombinant expression of wild-type and mutant enzymes
recombinant expression of wild-type and mutant enzymes with a Flag-tag beta-adducin tail and MARCKS domain tagged to it, or tagged with actin-binding domain (1-275 aa), repeat domain (303-525 aa), and PH domain (2197-2307 aa) of beta2-spectrin. Tag cleavage by prescission protease
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
IP6K1 knockdown in MEF cells
-
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
E192G
site-directed mutagenesis
E192Q
site-directed mutagenesis
K103A
site-directed mutagenesis
K213A
site-directed mutagenesis
K248A
the mutant shows a reduction in 1D-myo-inositol hexakisphosphate-stimulated ATPase activity of isofom PPIP5K2. The mutant shows a significant reduction in the rate of 1D-myo-inositol phosphate-independent ATPase activity of isofom PPIP5K2
K54A
site-directed mutagenesis
R213A
the mutant shows a reduction in 1D-myo-inositol hexakisphosphate-stimulated ATPase activity of isofom PPIP5K2
S347A/S359A
-
no IHPK2 activity
K217A
a kinase-dead mutant IP6K3, the catalytically inactive IP6K3 K217A mutant binds spectrin/adducin similarly to the wild-type enzyme
K226A/S334A
-
catalytically inactive
R133A
-
mutation of IP6K2 in its putative HSP90-binding motif, mutation of Arg133 abolishes IP6K2-HSP90 binding
R136A
-
mutation of IP6K2 in its putative HSP90-binding motif, mutation of Arg136 abolishes IP6K2-HSP90 binding
S118A/S121A
-
site-directed mutagenesis, no phosphorylation of IP6K1 mutant S118A-S121A in HEK293 cells. The mutant does not efficiently bind Myc-PLIN1 in HEK293 cells
S347A/S359A
-
site-directed mutagenesis, the mutant displays 3.5fold greater TAK1 activation following TNF-alpha, the mutant demonstrates a 6-10fold increase in NF-kappaB DNA binding following TNF-alpha compared with wild type IHPK2-expressing cells in which NF-kappa B DNA binding is inhibited
S85A
-
site-directed mutagenesis, the mutation does not influence its binding to Myc-PLIN1 in HEK293 cells
W131A
-
mutation of IP6K2 in its putative HSP90-binding motif, mutation of Trp131 modestly diminishes IP6K2-HSP90 binding, the catalytically impaired IP6K2-W131A does not induce cell death
additional information
Renatured/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
dialysis against renaturing buffer (25% sucrose, 0.1% Tween 40, 84 mM HEPES pH 7.5) after elution with denaturing buffer containing 150 mM imidazole
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
medicine